Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03618602
Other study ID # CH-020PI
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date April 25, 2018
Est. completion date July 2020

Study information

Verified date September 2019
Source Shanghai Theorion Pharmaceutical Co Ltd.
Contact Jian Hou, MD
Phone 00862168383144
Email houjian@medmail.com.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and efficacy of Bisthianostat in refractory or recurrent multiple myeloma patients.


Description:

This is a first-in-human, single center, open-label, single arm, dose escalating phase I study. This study will be conducted in 3 parts.

Phase A : Patients will receive single dose of bisthianostat to evaluate the single-dose pharmacokinetics and safety.

Phase B: After single-dose phase, patients will receive multiple dose bisthianostat for 4 weeks on day 1,4,11,14,18,21,25,28 to evaluate the multiple-dose pharmacokinetics and safety

Phase C: Patients will continue on the study if they benefit from the drug and not experience any serious side effects.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date July 2020
Est. primary completion date April 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Diagnosed as stage II or III (Durie-Salmon Staging System) multiple myeloma with disease progression or recurrence after at least two cycles of systemic antimyeloma treatment.

- Serum M protein= 5.0g / L, or urine M protein = 200mg / 24h, or serum free light chain = 200mg / L.

- Eastern Cooperative Oncology Group (ECOG) Performance Status of = 2.

- Expected survival of =3 months.

- Female participants of childbearing potential should have negative urine pregnancy test in screening period (accept previous test result within 14 days before screening), and must agree to adopt effective contraceptive measures within 14 days before receiving first dose of study drug, during the treatment period and within 28 days after final dose of study drug.

- Male participants must agree to adopt effective contraceptive measures and not allowed to donate sperms during the treatment period, and within 28 days after final dose of study drug.

- Hemoglobin = 80 g/L, Platelet=50×109/L (50,000/mm3), Absolute Neutrophil Count?1.0×109/L (1000 cells/mm3), Prothrombin time(PT) and activated partial thromboplastin time = 2 x Upper Limit of Normal (ULN)

- AST or ALT = 1.5 x ULN, total bilirubin= 1.5 x ULN;

- Serum Creatinine = 1.5 x ULN, glomerular filtration rate= 50 ml/min;

- NYHA Class I or II

- Written informed consent obtained prior to participation in the study

Exclusion Criteria:

- Pregnant or lactating women.

- Non-secretory multiple myeloma patients.

- Plasma cell leukemia patients.

- Received any anti-cancer medication or experimental drugs against multiple myeloma within 1 week before first dose of bisthianostat, any experimental treatment other than medication (eg. leukocyte donor/monocyte infusion) within 56 days before first dose of bisthianostat. Participation in any other drug or medical devices within 56 days before the study.

- Stem cell transplant planned on the following 28 days.

- Uncontrolled hypercalcemia after treatments, eg. saline infusion.

- Renal insufficiency required hemodialysis or peritoneal dialysis.

- NCI-CTCAE grade 2 Peripheral Neuropathy.

- Serious heart disease in the past 6 months, including angina requiring surgery, uncontrolled hypertension after anti-hypertensive treatments (Systolic blood pressure> 160 mmHg, Diastolic blood pressure>90mmHg); Myocardial infarction; Grade II-IV congestive heart failure; unstable angina.

- HIV, HCV or HBV (HBV-DNA > 20 IU/mL) infection.

- Patients with any other prior malignancy, except for skin basal cell carcinoma, cervical carcinoma in situ, breast carcinoma in situ, skin squamous cell carcinoma that have been treated and controlled.

- Imaging evidences show tumors have involved main blood vessels and nerves.

- Patients with significant central nervous system lesions.

- Patients with mental illness.

- Patients with history of alcohol or drug abuse, patients with allergy to the active ingredient or excipients of study drug, and patients who are unable or unwilling to receive the intravenous administration.

- Active infection (Bacteria, fungi, virus etc), fever with body temperature > 38 ? for reasons unknown.

- Other situations that investigator considers it's inappropriate for patients to participate in this study.

Study Design


Intervention

Drug:
Bisthianostat
Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.

Locations

Country Name City State
China Renji Hospital Shanghai Shanghai

Sponsors (2)

Lead Sponsor Collaborator
Shanghai Theorion Pharmaceutical Co Ltd. Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose of Bisthianostat To determine the maximum tolerated dose of Bisthianostat in refractory or recurrent multiple myeloma patients. Up to 24 months
Primary Treatment-related adverse events considered as dose-limiting toxicity To evaluate the severity of treatment-related AEs considered as dose-limiting toxicity. During the first cycle (4 weeks)
Secondary Peak Plasma Concentration (Cmax) To determine the Peak Plasma Concentration of Bisthianostat. During the first cycle (4 weeks)
Secondary Area under the plasma concentration versus time curve (AUC) To determine the Area under the plasma concentration versus time curve of Bisthianostat. During the first cycle (4 weeks)
Secondary Time of Peak Concentration (Tmax) To determine the time of peak concentration of Bisthianostat. During the first cycle (4 weeks)
Secondary Half life (T1/2) To determine the half-life of Bisthianostat. During the first cycle (4 weeks)
Secondary Objective Response Rate To evaluate the objective response rate in refractory or recurrent myeloma patients after bisthianostat treatments. Up to 1 month after last dose
Secondary Incidence of adverse events related to treatments To evaluate the incidence of adverse events that are related to treatments in refractory or recurrent myeloma patients Up to 1 month after last dose
Secondary Incidence of laboratory abnormalities related to treatments To evaluate the incidence of laboratory abnormalities that are related to treatments in refractory or recurrent myeloma patients Up to 1 month after last dose
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04083534 - First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) Phase 1/Phase 2
Terminated NCT02020941 - Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy Phase 2
Completed NCT01775553 - Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib Phase 2
Completed NCT01212952 - Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Terminated NCT01078441 - Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant Phase 2
Completed NCT01233921 - Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer N/A
Completed NCT00514137 - Sunitinib in Treating Patients With Relapsed Multiple Myeloma Phase 2
Completed NCT00306813 - Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT00078858 - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Phase 1/Phase 2
Completed NCT00047203 - Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 2
Active, not recruiting NCT03731832 - Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma Phase 2
Completed NCT00003196 - Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma N/A
Recruiting NCT03601624 - Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans Phase 2
Terminated NCT01954784 - Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma Phase 1
Recruiting NCT05020444 - TriPRIL CAR T Cells in Multiple Myeloma Phase 1
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Recruiting NCT04302324 - A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab Phase 2
Recruiting NCT06119685 - IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers Phase 1/Phase 2
Completed NCT00118170 - Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function Phase 1
Completed NCT00054353 - Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma Phase 1/Phase 2